83 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
28
Ending by 2030
Jan 2027
Next term end
13
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2028 · Low confidence
Also notable
Ends Sep 2037 · High confidence
Also notable
Ends no later than Feb 2038 · Low confidence
Immunoconjugates with an Intracellularly-Cleavable Linkage
US 7,999,083
The most cited patent in this portfolio, cited by 229 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Efficacy of ANTI-TROP-2-SN-38 Antibody Drug Conjugates for Therapy of Tumors Relapsed/Refractory to Checkpoint Inhibitors
US 10,266,605
Cited by 11 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2037.
Novel ANTI-PD-1 Checkpoint Inhibitor Antibodies That Block Binding of PD-L1 to PD-1
US 10,669,338
Cited by 18 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2038. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 16, 2027The maintenance fee for Anti-Histone Therapy in Acute Kidney Injury (US 10,351,621) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 2 fees due Feb 18 to 25, 2027 · next Feb 18
- 1 fee due Mar 17, 2027The maintenance fee for Therapy for Metastatic Urothelial Cancer with the Antibody-Drug Conjugate, Sacituzumab Govitecan (IMMU-132) (US 10,413,539) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 8, 2027The maintenance fee for Isolation, Detection, Diagnosis And/Or Characterization of Circulating TROP-2-Positive Cancer Cells (US 10,436,788) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
- 1 fee due May 10, 2027The maintenance fee for Stable Compositions of High-Concentration Allotype-Selected Antibodies for Small-Volume Administration (US 9,180,205) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 1 fee due Jul 5, 2027The maintenance fee for Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity (US 9,226,973) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Sep 8, 2027The maintenance fee for Methods of Treating Rapidly Progressive Glomerulonephritis Using Chimeric and Humanized Anti-Histone H4 Antibodies (US 9,278,129) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Humanized L243 Antibodies | 61 in force | to Jul 2033 |
| Chimeric and Humanized Anti-Histone Antibodies | 7 in force | to Feb 2034 |
| Efficacy of ANTI-TROP-2-SN-38 Antibody Drug Conjugates for Therapy of Tumors Relapsed/Refractory to Checkpoint Inhibitors | 2 in force | to Sep 2037 |
| T20 Constructs for Anti-HIV (Human Immunodeficiency Virus) Therapy And/Or Vaccines | 2 in force | to May 2036 |
| Isolation, Detection, Diagnosis And/Or Characterization of Circulating TROP-2-Positive Cancer Cells | 2 in force | to Apr 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,613,903 | Humanized L243 Antibodies In force · High confidence | In force | High confidence | |
| US 8,697,080 | Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments In force · High confidence | In force | High confidence | |
| US 9,184,781 | Humanized Antibodies and Methods of Humanizing Antibodies In force · High confidence | In force | High confidence | |
| US 7,612,180 | Humanized L243 Antibodies In force · High confidence | In force | High confidence | |
| US 7,563,433 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules In force · High confidence | In force | High confidence | |
| US 7,597,876 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules In force · High confidence | In force | High confidence | |
| US 7,993,626 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules In force · High confidence | In force | High confidence | |
| US 8,147,799 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules In force · High confidence | In force | High confidence | |
| US 8,147,800 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules In force · High confidence | In force | High confidence | |
| US 8,153,100 | Methods and Compositions for F-18 Labeling of Proteins, Peptides and Other Molecules In force · High confidence | In force | High confidence |
Also on record, not counted in the 83: 2 patents in force now held by others · 230 patents ended · 8 applications pending · 136 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.